Lyra Therapeutics, Inc.
LYRADelisted Apr 20, 2026- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001327273
Lyra Therapeutics, Inc. was delisted on Apr 20, 2026; its insiders filed their last Form 4 on May 15, 2026; 23 institutions reported holding it in 13F filings for Q4 2025, worth $747.3K in total; no superinvestor held it.
13F holders, Q4 2022
Institutional positions in Lyra Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- −1 vs. Q3 2022
- Shares held
- 19.1M
- −82.8K (−0.4%) vs. Q3 2022
- Total value
- $59.9M
- −$36.1M (−37.6%) vs. Q3 2022
- New holders
- 5
- 11 more added
- Sold out
- 6
- 6 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LYRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 1 | $51.1K |
| Q4 2025 | 23 | $747.3K |
| Q3 2025 | 26 | $2.93M |
| Q2 2025 | 30 | $4.42M |
| Q1 2025 | 57 | $3.23M |
| Q4 2024 | 54 | $5.54M |
| Q3 2024 | 62 | $8.36M |
| Q2 2024 | 51 | $9.06M |
| Q1 2024 | 79 | $283.4M |
| Q4 2023 | 60 | $222.0M |
| Q3 2023 | 45 | $124.8M |
| Q2 2023 | 39 | $138.4M |
| Q1 2023 | 31 | $38.1M |
| Q4 2022 | 37 | $59.9M |
| Q3 2022 | 38 | $96.0M |
| Q2 2022 | 38 | $108.9M |
| Q1 2022 | 28 | $20.2M |
| Q4 2021 | 34 | $22.4M |
| Q3 2021 | 37 | $60.8M |
| Q2 2021 | 46 | $56.0M |
| Q1 2021 | 50 | $87.6M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Lyra Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 34 | $0 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1 | $3 | 0.00% | +1 | New |
| Investors Research Corp | 15 | $47 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 113 | $355 | 0.00% | +3+2.7% | Added |
| CoreCap Advisors, LLC | 125 | $393 | 0.00% | +125 | New |
| FMR LLC | 450 | $1.41K | 0.00% | +450 | New |
| US Bancorp | 500 | $1.57K | 0.00% | 00.0% | Unchanged |
| Signaturefd, LLC | 500 | $1.57K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 500 | $2.00K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 491 | $2.00K | 0.00% | +333+210.8% | Added |
| Worth Asset Management, LLC | 650 | $2.04K | 0.00% | 00.0% | Unchanged |
| Ameliora Wealth Management Ltd. | 750 | $2.35K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3,397 | $10.7K | 0.00% | +303+9.8% | Added |
| Belpointe Asset Management LLC | 3,703 | $11.6K | 0.00% | +3,703 | New |
| Tower Research Capital LLC (TRC) | 4,786 | $15.0K | 0.00% | +1,296+37.1% | Added |
| Susquehanna International Group, LLP | 13,582 | $42.6K | 0.00% | −7,976−37.0% | Reduced |
| Citadel Advisors LLC | 25,277 | $79.4K | 0.00% | −11,859−31.9% | Reduced |
| Two Sigma Advisers, LP | 28,600 | $89.8K | 0.00% | −14,200−33.2% | Reduced |
| Northern Trust Corp | 29,829 | $93.7K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 34,721 | $109.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 37,200 | $117.0K | 0.00% | −2,800−7.0% | Reduced |
| State Street Corp | 37,580 | $118.0K | 0.00% | +2,537+7.2% | Added |
| Anson Funds Management LP | 39,127 | $122.9K | 0.04% | +39,127 | New |
| BlackRock Inc. | 40,114 | $126.0K | 0.00% | +1,099+2.8% | Added |
| Bank of America Corp | 101,754 | $319.5K | 0.00% | +7,124+7.5% | Added |
| Clearline Capital LP | 119,128 | $374.1K | 0.07% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 146,800 | $461.0K | 0.01% | +89,900+158.0% | Added |
| Geode Capital Management, LLC | 148,840 | $467.0K | 0.00% | +1,981+1.3% | Added |
| Ensign Peak Advisors, Inc | 302,235 | $949.0K | 0.00% | +239,025+378.1% | Added |
| Ikarian Capital, LLC | 343,685 | $1.08M | 0.45% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 592,417 | $1.86M | 0.27% | 00.0% | Unchanged |
| Vanguard Group Inc | 790,936 | $2.48M | 0.00% | +3160.0% | Added |
| VR Adviser, LLC | 924,170 | $2.90M | 0.49% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,777,251 | $5.58M | 1.20% | 00.0% | Unchanged |
| Pura Vida Investments, LLC | 2,157,298 | $6.77M | 1.14% | −353,004−14.1% | Reduced |
| Nantahala Capital Management, LLC | 2,220,830 | $6.97M | 0.63% | −25,000−1.1% | Reduced |
| Perceptive Advisors LLC | 9,146,730 | $28.7M | 0.83% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −19,496−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −18,908−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,772−100.0% | Sold out |
| HighMark Wealth Management LLC | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Close Asset Management Ltd | 0 | $0 | 0.00% | −50−100.0% | Sold out |